Tom Huang
Research Subjects
Tom Huang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bee-Chun Sun
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications - David I. Bellovin
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications - Haoyu Zhang
WuXi AppTec, Shanghai, P.R. China
19 shared publications - Kevin X. Chen
WuXi AppTec, Shanghai, P.R. China
19 shared publications - Nehal S. Parikh
Rutgers Cancer Institute, New Brunswick, New Jersey, USA
19 shared publications - Neil E. Bhola
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications
Latest Publications
- Open Access
- 1 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (9) , 1731-1742
Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
DNA-dependent protein kinase (DNA-PK), a driver of the non-homologous end-joining (NHEJ) DNA damage response pathway, plays an instrumental role in repairing double-strand breaks (DSB) induced by DNA-damaging poisons. We evaluate ZL-2201, an orally bioavailable, highly potent, and selective pharmacologic inhibitor of DNA-PK activity, for the treatment of human cancerous malignancies. ZL-2201 demonstrated greater selectivity for DNA-PK and effectively inhibited DNA-PK autophosphorylation in a concentration- and time-dependent manner. Initial data suggested a potential correlation between ataxia-telangiectasia mutated (ATM) deficiency and ZL-2201 sensitivity. More so, ZL-2201 showed strong synergy with topoisomerase II inhibitors independent of ATM status in vitro. In vivo oral administration of ZL-2201 demonstrated dose-dependent antitumor activity in the NCI-H1703 xenograft model and significantly enhanced the activity of approved DNA-damaging agents in A549 and FaDu models. From a phosphoproteomic mass spectrometry screen, we identified and validated that ZL-2201 and PRKDC siRNA decreased Ser108 phosphorylation of MCM2, a key DNA replication factor. Collectively, we have characterized a potent and selective DNA-PK inhibitor with promising monotherapy and combinatory therapeutic potential with approved DNA-damaging agents. More importantly, we identified phospho-MCM2 (Ser108) as a potential proximal biomarker of DNA-PK inhibition that warrants further preclinical and clinical evaluation. Significance: ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.
- 1 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (9) , 1731-1742
Open AccessDiscovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
DNA-dependent protein kinase (DNA-PK), a driver of the non-homologous end-joining (NHEJ) DNA damage response pathway, plays an instrumental role in repairing double-strand breaks (DSB) induced by DNA-damaging poisons. We evaluate ZL-2201, an orally bioavailable, highly potent, and selective pharmacologic inhibitor of DNA-PK activity, for the treatment of human cancerous malignancies. ZL-2201 demonstrated greater selectivity for DNA-PK and effectively inhibited DNA-PK autophosphorylation in a concentration- and time-dependent manner. Initial data suggested a potential correlation between ataxia-telangiectasia mutated (ATM) deficiency and ZL-2201 sensitivity. More so, ZL-2201 showed strong synergy with topoisomerase II inhibitors independent of ATM status in vitro. In vivo oral administration of ZL-2201 demonstrated dose-dependent antitumor activity in the NCI-H1703 xenograft model and significantly enhanced the activity of approved DNA-damaging agents in A549 and FaDu models. From a phosphoproteomic mass spectrometry screen, we identified and validated that ZL-2201 and PRKDC siRNA decreased Ser108 phosphorylation of MCM2, a key DNA replication factor. Collectively, we have characterized a potent and selective DNA-PK inhibitor with promising monotherapy and combinatory therapeutic potential with approved DNA-damaging agents. More importantly, we identified phospho-MCM2 (Ser108) as a potential proximal biomarker of DNA-PK inhibition that warrants further preclinical and clinical evaluation. Significance: ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 treatment exhibits potent antitumor efficacy in vivo.
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 treatment exhibits potent antitumor efficacy in vivo.
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Phenotypic effects of combining ZL-2201 and Doxorubicin
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Phenotypic effects of combining ZL-2201 and Doxorubicin
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Kinetics of Bleomycin-induced DNA-PK phosphorylation by ZL-2201
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Kinetics of Bleomycin-induced DNA-PK phosphorylation by ZL-2201
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Cellular efficacy of ZL-2201 across cancer cell lines
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Cellular efficacy of ZL-2201 across cancer cell lines
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).